CN1103593C - 协同组合物 - Google Patents

协同组合物 Download PDF

Info

Publication number
CN1103593C
CN1103593C CN96194050A CN96194050A CN1103593C CN 1103593 C CN1103593 C CN 1103593C CN 96194050 A CN96194050 A CN 96194050A CN 96194050 A CN96194050 A CN 96194050A CN 1103593 C CN1103593 C CN 1103593C
Authority
CN
China
Prior art keywords
amino
cis
oxathiolane
pyrimid
methylol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CN96194050A
Other languages
English (en)
Chinese (zh)
Other versions
CN1185110A (zh
Inventor
D·W·巴里
M·H·St·克莱尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ViiV Healthcare UK Ltd
Original Assignee
Wellcome Foundation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26306774&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN1103593(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9506490.3A external-priority patent/GB9506490D0/en
Priority claimed from GBGB9506489.5A external-priority patent/GB9506489D0/en
Application filed by Wellcome Foundation Ltd filed Critical Wellcome Foundation Ltd
Publication of CN1185110A publication Critical patent/CN1185110A/zh
Application granted granted Critical
Publication of CN1103593C publication Critical patent/CN1103593C/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Medicinal Preparation (AREA)
  • Cephalosporin Compounds (AREA)
CN96194050A 1995-03-30 1996-03-28 协同组合物 Expired - Lifetime CN1103593C (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB9506490.3 1995-03-30
GB9506489.5 1995-03-30
GBGB9506490.3A GB9506490D0 (en) 1995-03-30 1995-03-30 Antiviral combinations
GBGB9506489.5A GB9506489D0 (en) 1995-03-30 1995-03-30 Antiviral combinations

Publications (2)

Publication Number Publication Date
CN1185110A CN1185110A (zh) 1998-06-17
CN1103593C true CN1103593C (zh) 2003-03-26

Family

ID=26306774

Family Applications (1)

Application Number Title Priority Date Filing Date
CN96194050A Expired - Lifetime CN1103593C (zh) 1995-03-30 1996-03-28 协同组合物

Country Status (35)

Country Link
US (1) US6417191B1 (enExample)
EP (1) EP0817637B1 (enExample)
JP (1) JP2954357B2 (enExample)
KR (1) KR100542536B1 (enExample)
CN (1) CN1103593C (enExample)
AP (1) AP652A (enExample)
AT (1) ATE220551T1 (enExample)
AU (1) AU715213B2 (enExample)
BR (3) BR9607851B1 (enExample)
CA (1) CA2216634C (enExample)
CZ (1) CZ295940B6 (enExample)
DE (3) DE122005000029I2 (enExample)
DK (1) DK0817637T3 (enExample)
EA (1) EA000626B3 (enExample)
EE (1) EE04047B1 (enExample)
ES (1) ES2179193T3 (enExample)
FR (1) FR05C0022I2 (enExample)
GE (1) GEP20022647B (enExample)
HU (1) HU224010B1 (enExample)
IL (1) IL117727A (enExample)
LU (1) LU91171I2 (enExample)
MX (1) MX9707316A (enExample)
MY (1) MY115461A (enExample)
NL (1) NL300195I2 (enExample)
NO (2) NO313787B1 (enExample)
NZ (1) NZ306419A (enExample)
OA (1) OA10616A (enExample)
PL (1) PL187085B1 (enExample)
PT (1) PT817637E (enExample)
RO (1) RO117995B1 (enExample)
SI (1) SI0817637T1 (enExample)
SK (1) SK283825B6 (enExample)
TR (1) TR199701074T1 (enExample)
UA (1) UA60293C2 (enExample)
WO (1) WO1996030025A1 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0938321B1 (en) * 1996-06-25 2004-01-14 Glaxo Group Limited Combinations comprising vx478, zidovudine and 3tc for use in the treatment of hiv
US6113920A (en) * 1996-10-31 2000-09-05 Glaxo Wellcome Inc. Pharmaceutical compositions
TW536403B (en) * 1997-03-24 2003-06-11 Glaxo Group Ltd An ethanol and ethylenediaminetetraacetic acid free pharmaceutical composition comprising lamivudine and exhibiting antimicrobial preservative efficacy
GB9709945D0 (en) * 1997-05-17 1997-07-09 Glaxo Group Ltd A novel salt
WO1998052570A1 (en) * 1997-05-17 1998-11-26 Glaxo Group Limited Antiviral combinations containing the carbocyclic nucleoside 1592u89
AU769660B2 (en) * 1997-05-17 2004-01-29 Glaxo Group Limited Carbocyclic nucleoside hemisulfate and its use in treating viral infections
GB9809213D0 (en) * 1998-04-29 1998-07-01 Glaxo Group Ltd Pharmaceutical compositions
US6875773B1 (en) 1998-05-29 2005-04-05 Ben M. Dunn Combination therapy for treatment of FIV infection
CA2374198A1 (en) * 1998-05-29 1999-12-02 Maki Arai Combination therapy for treatment of fiv infection
GB9820417D0 (en) * 1998-09-18 1998-11-11 Glaxo Group Ltd Antiviral combinations
US6432966B2 (en) 1999-10-29 2002-08-13 Smithkline Beecham Corporation Antiviral combinations
US7074417B2 (en) * 2000-10-13 2006-07-11 Advancis Pharmaceutical Corporation Multiple-delayed release anti-viral product, use and formulation thereof
AP2220A (en) * 2001-05-11 2011-03-24 Cipla Medpro Pty Ltd Pharmaceutical composition.
AR040242A1 (es) * 2002-06-04 2005-03-23 Glaxo Group Ltd Composiciones farmaceuticas
AU2004206821C1 (en) 2003-01-14 2009-10-01 Gilead Sciences, Inc. Compositions and methods for combination antiviral therapy
MXPA05010081A (es) 2003-03-24 2005-11-23 Hoffmann La Roche Bencil-piridazinonas como inhibidores de transcriptasa inversa.
PT1692516E (pt) 2003-10-24 2011-03-07 Immunaid Pty Ltd Método de terapia
TWI471145B (zh) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
JP2009515826A (ja) 2005-10-19 2009-04-16 エフ．ホフマン−ラ ロシュ アーゲー フェニル−アセトアミドｎｎｒｔ阻害剤
JP5415957B2 (ja) 2006-12-13 2014-02-12 エフ．ホフマン−ラ ロシュ アーゲー 非ヌクレオシド逆転写酵素阻害剤としての２−（ピペリジン−４−イル）−４−フェノキシ−又はフェニルアミノ−ピリミジン誘導体
WO2008095263A1 (en) * 2007-02-09 2008-08-14 Alphapharm Pty Ltd A dosage form containing two or more active pharmaceutical ingredients in different physical forms
AU2010251880B2 (en) 2009-05-27 2015-07-30 Biotempus Pty Ltd Methods of treating diseases
BR112012018670A2 (pt) 2010-01-27 2018-02-06 Glaxosmithkline Llc combinação, uso de um composto, composição farmacêutica, e, pacote de paciente
HK1220390A1 (zh) 2013-08-29 2017-05-05 Teva Pharmaceutical Industries Ltd. 包括恩曲他滨，替诺福韦，达芦那韦和利托那韦的单位剂型以及包含达芦那韦和利托那韦的单体片剂
WO2015155673A1 (en) 2014-04-08 2015-10-15 Teva Pharmaceutical Industries Ltd Unit dosage form comprising emtricitabine, tenofovir, darunavir and ritonavir
EP4578865A3 (en) 2014-08-12 2025-07-30 Monash University Lymph directing prodrugs
CN108137482B (zh) 2015-09-08 2024-03-15 莫纳什大学 定向淋巴的前药
EP4306524A3 (en) * 2017-08-29 2024-09-11 PureTech LYT, Inc. Lymphatic system-directing lipid prodrugs
US11883497B2 (en) 2017-08-29 2024-01-30 Puretech Lyt, Inc. Lymphatic system-directing lipid prodrugs
US11608345B1 (en) 2017-12-19 2023-03-21 Puretech Lyt, Inc. Lipid prodrugs of rapamycin and its analogs and uses thereof
US11304954B2 (en) 2017-12-19 2022-04-19 Puretech Lyt, Inc. Lipid prodrugs of mycophenolic acid and uses thereof
JP2023514147A (ja) 2020-02-05 2023-04-05 ピュアテック・エル・ワイ・ティ・インコーポレイテッド 神経ステロイドの脂質プロドラッグ

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992015309A1 (en) * 1991-03-06 1992-09-17 The Wellcome Foundation Limited Antiviral nucleoside combination
CN1068570A (zh) * 1991-05-16 1993-02-03 格拉克索公司 抗病毒组合物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4724232A (en) * 1985-03-16 1988-02-09 Burroughs Wellcome Co. Treatment of human viral infections
US5047407A (en) 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
US5122517A (en) 1988-06-10 1992-06-16 Regents Of The University Of Minnesota Antiviral combination comprising nucleoside analogs
GB8815265D0 (en) * 1988-06-27 1988-08-03 Wellcome Found Therapeutic nucleosides
US5204466A (en) 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
GB9009861D0 (en) 1990-05-02 1990-06-27 Glaxo Group Ltd Chemical compounds
ATE184787T1 (de) * 1992-05-13 1999-10-15 Wellcome Found Therapeutische kombinationen
US5723490A (en) 1992-09-08 1998-03-03 Vertex Pharmaceuticals Incorporated THF-containing sulfonamide inhibitors of aspartyl protease
GB9417249D0 (en) 1994-08-26 1994-10-19 Wellcome Found A novel salt
US5869461A (en) 1995-03-16 1999-02-09 Yale University Reducing toxicity of L-nucleosides with D-nucleosides
DE69718168T2 (de) 1996-06-25 2003-10-23 Glaxo Group Ltd., Greenford Zusammensetzungen enthaltend vx478, zidovudine und 159u89 für die verwendung in der behandlung von hiv
EP0938321B1 (en) 1996-06-25 2004-01-14 Glaxo Group Limited Combinations comprising vx478, zidovudine and 3tc for use in the treatment of hiv
DE10226522A1 (de) 2002-06-14 2003-12-24 Degussa Verwendung von Übergangsmetallkomplexen mit stickstoffhaltigen mehrzähnigen Liganden als Bleichkatalysator und Bleichmittelzusammensetzung

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992015309A1 (en) * 1991-03-06 1992-09-17 The Wellcome Foundation Limited Antiviral nucleoside combination
CN1068570A (zh) * 1991-05-16 1993-02-03 格拉克索公司 抗病毒组合物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SCRIP WORLD PHARMACEU 1994-10-25 TISDALEM, 等人RAPID IN - *

Also Published As

Publication number Publication date
CA2216634C (en) 2004-07-20
BRPI9612992B1 (pt) 2020-08-04
IL117727A0 (en) 1996-07-23
DE69622386T2 (de) 2003-02-13
IL117727A (en) 1999-11-30
CN1185110A (zh) 1998-06-17
CZ295940B6 (cs) 2005-12-14
NO2005014I2 (no) 2008-02-11
NO2005014I1 (no) 2005-06-06
BR9607851B1 (pt) 2009-01-13
KR19980703420A (ko) 1998-11-05
SK283825B6 (sk) 2004-02-03
WO1996030025A1 (en) 1996-10-03
CZ309097A3 (cs) 1998-05-13
AP652A (en) 1998-06-19
NO974510L (no) 1997-09-29
PL187085B1 (pl) 2004-05-31
EE04047B1 (et) 2003-06-16
EP0817637B1 (en) 2002-07-17
FR05C0022I1 (enExample) 2005-06-10
KR100542536B1 (ko) 2006-03-23
EP0817637A1 (en) 1998-01-14
NO974510D0 (no) 1997-09-29
DK0817637T3 (da) 2002-11-11
PL322532A1 (en) 1998-02-02
EE9700240A (et) 1998-04-15
SI0817637T1 (en) 2002-10-31
HUP9801571A2 (hu) 1999-01-28
BRPI9607851B8 (pt) 2019-11-05
NL300195I2 (nl) 2005-11-01
LU91171I2 (fr) 2005-07-04
OA10616A (en) 2001-03-15
NZ306419A (en) 2000-01-28
PT817637E (pt) 2002-11-29
ES2179193T3 (es) 2003-01-16
NL300195I1 (nl) 2005-08-01
TR199701074T1 (xx) 1998-02-21
US6417191B1 (en) 2002-07-09
AU715213B2 (en) 2000-01-20
AP9701089A0 (en) 1997-10-31
LU91171I9 (enExample) 2018-12-28
EA000626B1 (ru) 1999-12-29
RO117995B1 (ro) 2002-12-30
ATE220551T1 (de) 2002-08-15
FR05C0022I2 (enExample) 2005-10-21
UA60293C2 (uk) 2003-10-15
HUP9801571A3 (en) 2001-04-28
JPH10511682A (ja) 1998-11-10
DE122005000029I1 (de) 2005-10-06
NO313787B1 (no) 2002-12-02
BR9607851A (pt) 1998-07-21
SK129597A3 (en) 1998-07-08
GEP20022647B (en) 2002-03-25
MX9707316A (es) 1997-11-29
JP2954357B2 (ja) 1999-09-27
HK1009401A1 (en) 1999-09-10
EA199700203A1 (ru) 1998-02-26
HU224010B1 (hu) 2005-04-28
CA2216634A1 (en) 1996-10-03
DE69622386D1 (de) 2002-08-22
MY115461A (en) 2003-06-30
DE122005000029I2 (de) 2006-04-27
EA000626B3 (ru) 2016-04-29
AU5497296A (en) 1996-10-16

Similar Documents

Publication Publication Date Title
CN1103593C (zh) 协同组合物
RU2012133528A (ru) Способ лечения аутоиммунного демиелинизирующего заболевания центральной нервной системы (варианты)
EA014189B1 (ru) Применение флибансерина для лечения расстройств полового влечения в предклимактерический период
WO2016184381A1 (zh) 右旋奥拉西坦在制药领域中的应用
CN1051550C (zh) 作为抗病毒剂的4－[2－氨基－6－(环丙基氨基)－9h－嘌呤－9－基]－2－环戊烯－1－甲醇琥珀酸盐
TW469132B (en) Antiviral combinations
JP2002512979A (ja) アバカビール、ラミブジンおよびジドブジンを含んでなる均質な医薬組成物
CN1354662A (zh) 奥桑唐特在用于治疗心情疾病的药物制剂中的应用
US20020002180A1 (en) Antiviral combinations
HRP980264A2 (en) Antiviral combinations
KR20010021796A (ko) 선택성 세로토닌 재흡수 억제제 (ｓｓｒｉ)를 사용하는심장 질환의 치료 및 예방법
CN1317971A (zh) 包含拉米夫定和阿巴卡维的抗病毒联合用药物
KR20000022225A (ko) Hiv 치료에 사용하기 위한 vx478, 지도부딘 및(또는)1592u89를 포함하는 배합물
HK1009401B (en) Synergistic combinations
WO2000018383A2 (en) Antiviral combinations comprising (s)-2- ethyl-7- fluoro-3- oxo-3,4- dihydro-2h- quinoxaline-1- carboxylic acid isopropyl ester
TWI230610B (en) Dosage kits and pharmaceutical compositions for treating HIV infections
JP2001509786A (ja) Ｈｉｖの治療に使用するためのｖｘ４７８、ジドブジン、および／または１５９２ｕ８９を含んでなる組合わせ
CN107583032A (zh) 一种治疗肾小球肾炎的药物复方制剂
CN1518983A (zh) 协同抗乙肝病毒（hbv）的药物组合物
WO2000016754A2 (en) Antiviral combinations comprising lamivudine and lobucavir
CN1762377A (zh) 含有齐多夫定和丙戊酸或其盐的药用组合物
CN1454089A (zh) 糖尿病治疗剂
WO2012095726A1 (en) Pharmaceutical combination containing glucosamine salts and paracetamol for the treatment of osteoarthritis

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
ASS Succession or assignment of patent right

Owner name: VIIV HEALTHCARE UK LTD.

Free format text: FORMER OWNER: THE WELLCOME FOUNDATION LTD. (GB) 183-193 EUSTON ROAD. LONDON. N.W.1. ENGLAND

Effective date: 20140224

TR01 Transfer of patent right

Effective date of registration: 20140224

Address after: The Middlesex County

Patentee after: Viiv Healthcare Uk Ltd

Address before: The Middlesex County

Patentee before: Wellcome Foundation Group

TR01 Transfer of patent right
CX01 Expiry of patent term

Granted publication date: 20030326

EXPY Termination of patent right or utility model